ff2 REFJPORT: Final Report-~Vs ~

Similar documents
Neutralization of Micrurus distans distans venom by antivenin (Micrurus fulvius)

Fish Envenomation. Tony Alleman, MD MPH FACOEM UHM

TOXOIDING OF SNAKE VENOM AND EVALUATION OF IMMUNOGENICITY OF THE TOXOIDS

Name Class Date. After you read this section, you should be able to answer these questions:

What causes heartworm disease?

VENOMS OF CORAL SNAKES (MICRURUS SPP.): REPORT ON A MULTIVALENT ANTIVENIN FOR THE AMERICAS

Feline Heartworm Antibody Test Kit. In vitro diagnostic test for the detection of antibodies to Dirofilaria immitis in feline serum or plasma.

1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT

CANINE HEARTWORM DISEASE

Heartworm Disease in Dogs

SUMMARY OF PRODUCT CHARACTERISTICS. Pentoject, Pentobarbitone Sodium 200 mg/ml Solution for Injection

Vertebrates. Vertebrate Characteristics. 444 Chapter 14

AMOXICILLIN AND CLAVULANIC ACID TABLETS Draft proposal for The International Pharmacopoeia (February 2018)

PCR detection of Leptospira in. stray cat and

EU Statistical Data of all uses of animals

EU Statistical Data of all uses of animals

Ultra-Fast Analysis of Contaminant Residue from Propolis by LC/MS/MS Using SPE

5 Dangerous Venom Types Thailand Snakes. Thailand Snake Venom Types:

Materials and Methods: Anti-snake venom activities of Asparagus racernosus

MARBOCYL 10% SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

Physician Veterinarian Do you have the Bayer Spirit?

DP.1. Control tables

DP.1. Control tables

Animals used under 7 (2) of the Animal Protection Act by species

COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE

Procedure # IBT IACUC Approval: December 11, 2017

VOL. XXIII NO. II THE JOURNAL OF ANTIBIOTICS 559. ANTIBIOTIC 6640.* Ill

EC-AH-011v1 January 2018 Page 1 of 5. Standard Operating Procedure Equine Center Clemson University

Summary of Product Characteristics

Venom Research at Natural Toxins Research Center (NTRC)

[ APPLICATION NOTE ] Analysis of Ketamine and Xylazine in Rat Tissues Using the ACQUITY UPLC with 2D Technology APPLICATION BENEFITS INTRODUCTION

IOWA STATE UNIVERSITY Institutional Animal Care and Use Committee. Blood Collection Guidelines

SUMMARY OF PRODUCT CHARACTERISTICS

Jess Weidman, DVM, DACVIM- Cardiology CVCA Cardiac Care for Pets Dogwood Veterinary Emergency and Specialty

European Public MRL assessment report (EPMAR)

SUMMARY OF PRODUCT CHARACTERISTICS

Australian and New Zealand College of Veterinary Scientists. Membership Examination. Veterinary Anaesthesia and Critical Care Paper 1

SUMMARY OF PRODUCT CHARACTERISTICS. Euthasol vet. 400 mg/ml, solution for injection (AT, BE, DK, EE, EL, FI, IE, IS, LT, LU, LV, NO, PL, RO SE, UK)

SUMMARY OF PRODUCT CHARACTERISTICS

AN ABSTRACT OF THE THESIS OF. Title: CHEMICAL STABILIZATION AND PHARMACOLOGICAL CHARACTERIZATION. Lavern J. Weber

A-l. Students shall examine the circulatory and respiratory systems of animals.

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS VIRBAGEN OMEGA - EN 1

1 iv. 00 lad I 00 EDGEW00D ARSENAL ^ TECHNICAL REPORT. DOSE-RESPONSE RELATIONSHIP OF CRUDE COBRA VENOM {Naja naja) IN THE DOG

NEONATAL Point Prevalence Survey. Ward Form

Withdrawal period: 93 days Milk: Not authorised for use in animals producing milk for human consumption.

(D) fertilization of eggs immediately after egg laying

Metacam 1.5 mg/ml oral suspension for dogs

NOTES IMMUNOGENICITY IN MONKEYS OF A COMBINED TOXOID FROM THE MAIN TOXIC PRINCIPLES SEPARATED FROM HABU SNAKE VENOM

6/20/2018. A Public Benefit Corporation. A First-in-Class Snakebite Antidote. Discovery to Accelerated Development

Sites of IM injections : 1. Ventrogluteal site: site is in the gluteus medius muscle, which lies over the gluteus minimus. 2. Vastus lateralis site:

Correlation of. Animal Science Biology & Technology, 3/E, by Dr. Robert Mikesell/ MeeCee Baker, 2011, ISBN 10: ; ISBN 13:

SUMMARY OF PRODUCT CHARACTERISTICS

Therapeutic apheresis in veterinary

Biohazard: yes no Radioisotopes: yes no Chemical Carcinogen: yes no Agent: Agent: Agents: Project Title: Objective:

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS

Public Assessment Report Scientific discussion

EU Statistical Data of all uses of animals

Mouse Formulary. The maximum recommended volume of a drug given depends on the route of administration (Formulary for Laboratory Animals, 3 rd ed.

SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT

BOX 1. NAME OF THE VETERINARY MEDICINAL PRODUCT. Hymatil 300 mg/ml solution for injection for cattle and sheep Tilmicosin

Mechanism of a Crocodile s Circulatory System

UT HEALTH EMERGENCY MEDICINE & TRAUMA GUIDELINES

ASSESSMENT Theory and knowledge are tested through assignments and examinations.

READER S DIGEST OVERVIEW: BIGHORN SHEEP. Peregrine Wolff, DVM

Pain Management in Racing Greyhounds

ANTIBIOTICS IN PLASMA

The Impact of Translactational Delivered Meloxicam Analgesia on Biomarkers of Pain and Distress after Piglet Processing

Extraction and Cleanup Protocols for LC-MS/MS Multiresidue Determination of Veterinary Drugs in Tissue and Milk Samples

Anthony Karabanow, MD

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

BREATHING WHICH IS NOT RESPIRATION

LUPIN LIMITED SAFETY DATA SHEET. Section 1: Identification MADE IN INDIA

Hendra virus: Important information for all horse owners. An update on Hendra virus The Hendra vaccine

MOXIFLOXACIN HYDROCHLORIDE (MOXIFLOXACINI HYDROCHLORIDUM) Draft proposal for The International Pharmacopoeia. (January 2018)

Day 90 Labelling, PL LABELLING AND PACKAGE LEAFLET

SUMMARY OF PRODUCT CHARACTERISTICS

RABIES CONTROL INTRODUCTION

Anesthesia Check-off Form

Dexmedetomidine. Dr.G.K.Kumar,M.D.,D.A., Assistant Professor, Madras medical college,chennai. History

SUMMARY OF PRODUCT CHARACTERISTICS

Some important information about the fetus and the newborn puppy

Ohio State Board of Pharmacy Compliance in Veterinary Practice

Health Products Regulatory Authority

Screening 36 Veterinary Drugs in Animal Origin Food by LC/MS/MS Combined with Modified QuEChERS Method

GUIDELINES FOR ANESTHESIA AND FORMULARIES

Spencer Greene, MD, MS, FACEP, FACMT

SUMMARY OF PRODUCT CHARACTERISTICS

Methods. Objective. Results

Company: Richter Pharma AG MUTUAL RECOGNITION PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT

EMEDOG 1mg/ml Solution for injection for dogs. Part I ADMINISTRATIVE DATA AND SUMMARY OF THE DOSSIER

PG 600. S ame time. same place. The management tool in swine reproduction

WHO/SEARO GUIDELINES FOR THE CLINICAL MANAGEMENT OF SNAKE BITES IN THE SOUTHEAST ASIAN REGION

SUMMARY OF PRODUCT CHARACTERISTICS. KELAPRIL 2.5 mg, film coated tablets for dogs and cats [FR] KELAPRIL 2,5 film coated tablets for dogs and cats

FLOXYME 50 mg/ml SOLUTION FOR USE IN DRINKING WATER

Pharm 262: Antibiotics. 1 Pharmaceutical Microbiology II DR. C. AGYARE

Feline and Canine Internal Parasites

USA Product Label LINCOCIN. brand of lincomycin hydrochloride tablets. brand of lincomycin hydrochloride injection, USP. For Use in Animals Only

Gastric Dilatation-Volvulus

Transcription:

PRFESINA SAASOCIATION LsnesoutUniversity of Southern California Medical Center TITL: Sow~ Chemical and Zootoxicological Properties of Stingray Venom NAME OF AUTHOR: Findlay E. Russell, M.D. DATE OF BSUE: April 1, 1967 - %rch 31, 1972 ff2 REFJPORT: Final Report-~Vs ~ J"C0NIRACTOR: ONR CONTRACT: Professional Staff Association of the 1AC/USC Medical Center 1739 North Griff in Avenue Los Ageles, California 90031 Nwmber N oool4i-67-c-0391 TASK IRU1S3E: M~ 305-786 ;./ 7,(. PSA P1RGTECT: 9-108-0-0 J~ Reproduction in whole or in part is permitted for any purpose 'A of the United States Government. Distribution of this document is unlimited. ::NATIONAL Sby TECHNICAL INFORMATION SERVICE SP~holgQd, V 1 I5 -.--.- ~f~ Ito- 'i ~ Y 1fi' f 1739NO~lH RIFFN AENU 4 OS ANGELES, CALIFORNIA 5,0031 TELEPHONE (213) 2234011.739 NORT GRFFNAVNU

918 LAIJIEI NOTCE THIS DOUETIS BEST QUALITY AVAMABLE. T COPY URNISHED TO DTIC CONTAINED A SIGNIFICANT NUMBER OF PAGES WHICH TS BET PAGS WICH DO NOT. REPRODUCE LEGIBLY. REPRODUCED FROM BEST AVAILABLE COPY

-777-7 -. 7' Duiring the past five years a definitive chemnical and pharmacological study has been carried out on the venom of' the stingrays, particularly the round 42 cies is responsible for xmny hundreds of' injuries yearly along,7 California stingray Urobatis halleri, common to the Southern California coas. This spe- beaches, and its related species are implicated in several thousand injuries per year along North American coastal shores. The m'anagement of stings by these elasmobranchs is unusua.lly successfully instituted by the lifeguard and beach services, who ha.ve received training over the years from the Laboratory of' Neurological Research. In 1960, 104i cases of' stingray injuries were seen at emergency hospital facilities. In 1970, only 27 patients were seen, even though the incidence of' reported stings was almost the same. The statistics reveal the success of' fi-rst-aid measures applied by the beach services. Du~ring the past several years an intensive study has been ma~de of' the chemistry and pharma~cology of' the venom of this fish. Its relative instability lias made it difficult, up until this past year, to carry out the necessary isolation characterization and pharmacological studies. However, during the past year the extraction of the venom with 0.05M phosphate buffer containing 10.314 Cleland's reagent has given a produc,,'- which is stable, and has Mude it possible to conduct a number of' chemical and toxicological studies. The lethsl fraction of -the venom is a protein of nmedium molecular weight, but apparently bound with an enzymue, or some other substance, which makes its separation as a pvre substance very difficult. Studies on the purification of' the lethal and pain-producing fractions are in progress. Pharmucological studies confirm the earlier findings of Russell airl van Harrev-eld, and indicate that iii severe envenomation, secondary shock can occur and can lead to death. The venon has no effect on nouromu.scular transmission or on nerve activity, although it produces severe, intense pain.i

A series of studies on the in vitro neutralization of Urobatis hialleri venom with antivenins prepared against the bat stingray Mlidbatis californicus and. the rounmd stingray U.castexi were carried out. The antivenins were prepared in the conventional manner, tha.t is, by giving successively increasing doses of the c.^ude venom to horses over a 17-week period, ma-intainin; the horses on a maintenance dose for three weeks, then drc.wing off designated amounts of blood for processing. The serum was processed by ammonium sulfate precipitation and pepsin digestion,, according to WHO requiirements. The venom was prepared by the batch method (Schaeffer et al., Toxicon 9. I 69, 1971), reconstituted with 0.05 M phosplate buffer) phj 7.14, in 0.9 percent NaCl at 50 C. The concentration used in all experiments was 10 ing pe-r ml. The extract was centrifuged for 15 minutes at 5,000 rpm and the precipitate discarded. The venom protein concentration vas determined and a lethality determination made in mice, using the intravenous route. One ml of the M. californicus antivenin neutralizes the lethal activity........of 10 mg of bat stingray venomn. One ml of the U. castexi antivenin neutralizes the lethal activity of 5 1 of this stingraysvnm To a rn'dbr of 1.0 ml samples of U. balleri venom, 0.05, 0.20, 0.50 and 1.00 ml of one or the othor of thc two antivenins were addfd. Each mixcture was agitated then maintained for one hour at 50 C. The mixture was then injected into mice and tha effect of the antivenin on survival rate at 24f hours was determined. The M4. calif ornicun antivemnin provided little protection against the lethal activity of 'U. hal].eri venom. Only at 1.0 ml of antivenin per m.l of veo a there any seemingly eignificant protection. The U. castexi gave s ow px'...~,ction at the 0.20 level, the 0.50 level and the 1.00 level. At the......

V.F last level the amount of venom required for the LD 50 had increased threefold. It is apparent that there is some significant cross protection between the antivenins of these two stingray species. Further iminochemical work is in progress on the venoms of four Urobatis species. Using various methods of extraction, particularly the batch and aspiration methods, as previously described for studies with Scorpaena guttata venom, certain chemical and physiopharmacological properties of the venoms of z six species of stingrays were determined. b. Employing gel filtration and ion-exchange chromatography it was possible to separate the venom into five biologically active fractions and at least six additional protein fractions, none of which showed a deleterious effect " on the cardiovascular survey preparation, the nammlian nerve-muscle preparation, the crayfish nerve-muscle preparation or the frog heart-lung preparation. The principal toxic and lethal fraction appears to be a very unstable protein #1I having a molecular weight of from 300.000-800,000. It is unstable in cystine, <.. reduced glutathione and parachloromercuribenzoate, and only slightly less unstable in EDTA. It was more stable in 10-3 Cleland's reagent, which was i used in some of the separation procedures The mechanism for the hypotensive crisis produced by lethal doses of the venom and the lethal venom fraction was investigated. large doses of the venom caused an immediate hypotensive crisis. Although this crisis reflected both direct and indirect actions, the chief effect was on the heart. Firos, second,and third degree blocks. were seen in all animals receiving large doses of the venom. Lesser amounts also produced cardiac standstill or damage, as well as marked pooling in the pulmonar'y circulation (in the cat) and the portal circulation (in the dog). With lesser amounts, cardiac dynamics became a less,bvious cause of the hypoctnsive crisis and the changes in the parameters of 'ius c au &

A the pulmonary and portal systems arpeared to play the more responsive role. Although the exact mechanism has not yet been determined, it would appear that vasoconstriction on the postcapillary side of the lung is the primary target area. The vasoconstriction leads to a decreased systemic arterial. pressure with a subsequent decrease in circulating volume to the right heart. Pulmonary artery pressure is increased while pulmonary flow is decreased. The capillary bed becomes distentcd and thrcmbi my be formed, leading to further pulmonary complications. The blood supply to the central nervous system is reduced causing cerebral anemia and changes in the central nervous system, particularly provoking a respiratory deficit. These and other changes in the cardiovascular parameters were investigated. PIAD FOR FUTURE Although the contract has been terminated, some further study will be given to the various properties and activities of the venom. venom-producing cells of the glandular triangle will be Made, A study of the using the electron microscope. 4-.-